Please login to the form below

Not currently logged in
Email:
Password:

Avanir Pharmaceuticals

This page shows the latest Avanir Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Avanir to co-promote Merck's diabetes drugs in the US

Avanir to co-promote Merck's diabetes drugs in the US

Merck &Co and Avanir Pharmaceuticals have entered an agreement to co-promote Merck's portfolio of sitagliptin-based diabetes products in the US. ... Rohan Palekar, chief commercial officer at Avanir, confirmed Merck's ambitions in the area.

Latest news

  • Genzyme appoints MS and rare diseases business leaders

    He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

  • Coronary conundrums

    Moderate to severe chronic pain. US. Dextromethorphan/quinidine. Nuedexta (Avanir Pharmaceuticals). Pseudobulbar affect. ... US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.

  • Pharma news in brief

    AZ buys into new cholesterol treatment. AstraZeneca has agreed to pay US biotech firm Avanir Pharmaceuticals up to £195m in cash and conditional milestones in a licensing deal for cardiovascular products, ... including Avanir's reverse cholesterol

  • British Bulldog

    AZ is also developing, in conjunction with the US Avanir Pharmaceuticals, a new type of cholesterol-lowering pill. ... Another pharma group in the FTSE 100 index, Shire Pharmaceuticals, also moved smartly higher thanks to the weak pound and a

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. †† Ariad Pharmaceuticals / Otsuka

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga. ... JV. Speciality pharmaceuticals. 200. Merck &Co /. Avanir Pharmaceuticals. Co-promotion. Januvia, Janumet and Jamumet XR in nursing homes.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology portfolio, Marqibo for leukaemia (FDA approved). ... 121. ‡ Optinose / Avanir Pharmaceuticals. Licence. Breath Powered intranasal sumatriptan for migraine (p3).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics